Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 3/20 | 0.39 |
| ▸ | GBA2 | Q9HCG7 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NGLY1 | Q96IV0 | 1/20 | 0.39 |
| ▸ | GANAB | Q14697 | 1/20 | 0.39 |
| ▸ | QDPR | P09417 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15314573 | 1.00 | NCF1 (0.43) | NCF1GBA1GBA2GAACYP1A2 | |
| SCHEMBL18122006 | 1.00 | NCF1 (0.43) | NCF1GBA1GBA2GAACYP1A2 | |
| SCHEMBL5321574 | 0.85 | — | — | |
| SCHEMBL5154229 | 0.85 | — | — | |
| SCHEMBL8205902 | 0.85 | — | — | |
| SCHEMBL5319624 | 0.85 | — | — | |
| SCHEMBL8320721 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL28185007 | 0.83 | GAA (0.38) | NCF1GBA1GBA2GAACYP1A2 | |
| SCHEMBL16925361 | 0.83 | CA1 (0.48) | NCF1GBA1GBA2GAACYP1A2 | |
| SCHEMBL16903315 | 0.83 | CA1 (0.48) | NCF1GBA1GBA2GAACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160289212-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2016-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289212-A1 | HEPATITIS B ANTIVIRAL AGENTS | ZC3HAV1, HAVCR2, SLC10A1 | NCF1 1351/4885GBA1 624/4885GBA2 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.